During the upcoming Society of Immunotherapy in Cancer (SITC) 2025 Annual Meeting, held November 7-9, 2025, and during the American Society of Hematology (ASH) 2025 Annual Meeting, held December 6-9, 2025, Verismo Therapeutics, a subsidiary of HLB Innovation developing CAR T-Cell Therapies based on the company’s novel KIR-CAR platform technology,* will present new preclinical and translational data supporting the advancement of its clinical pipelines, SynKIR™-110 and SynKIR™-310.
Oral and Poster presentation highlighting the development of potent Novel CAR T-cell therapies.
Verismo’s multi-chain KIR-CAR technology, including the assets SynKIR™-110 and SynKIR™-310, is currently included in various clinical trials.
The company’s KIR-CAR platform technology uses a modified NK cell-derived receptor and DAP12 pairing to improve T-cell functional persistence and reduce exhaustion, thereby enhancing efficacy against challenging tumors.
The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B-cell-associated disorders and malignancies.
STAR-101 Study
This first-in-human (FIH) STAR-101 study (NCT05568680) is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 in subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, or cholangiocarcinoma.
Mesothelioma
Mesothelioma is a rare, aggressive cancer, with more than 2,500 people diagnosed annually in the United States and 30,000 globally. [1]
Exposure to asbestos causes most cases of mesothelioma. [2] Asbestos was used in many consumer products, automobile parts, and building materials in the 20th century before scientists learned of its health dangers. The potential for asbestos exposure in the United States peaked in the 1970s but has since declined as U.S. asbestos mines were closed and asbestos-containing products and materials were withdrawn from the market.
The decline in asbestos exposure is reflected in lower mesothelioma incidence rates. However, people can still be exposed to asbestos in some consumer products and older buildings.
CELESTIAL-301 study
SynKIR™-310 is being studied in the CELESTIAL-301 study (NCT06544265), a first-in-human (FIH) trial to assess the safety, feasibility, and preliminary efficacy of a single intravenous (IV) dose in participants with relapsed/refractory B-NHL.
The scheduled presentations will include:
SITC 2025 Annual Meeting
During the SITC annual meeting in the Gaylord National Resort and Convention Center, National Harbor, Maryland, scientists will present 3 presentations.
- An oral and a poster presentation on new preclinical in vitro and in vivo results to investigate functionality, safety, and tumor killing of SynKIR™-110, Verismo’s lead pipeline targeting mesothelin
- Location: Gaylord National Resort & Convention Center, National Harbor 2-3
- Abstract Number: 298
- Abstract Title: A Novel NK-cell based Split-Signaling Killer Immunoglobulin Receptor (KIR)-Based CAR T Targeting Mesothelin, SynKIR-110, Shows Increased Safety Profile and Increased Efficacy in vitro and in vivo
- Presenting Author: Nora Yucel, PhD
- Oral Session Title: Oral Abstract Session 2
- Oral Session Date and Time: Friday, Nov. 7, 2025: 4:45PM – 5:00PM
- Poster Session Title: Exhibits and Poster Viewing
- Poster Session Date and Time: Saturday, Nov 8, 2025: 12:15 – 1:45 PM, 5:10 – 6:35 PM
- A poster presentation on immunohistochemistry (IHC) detection of mesothelin to support further development of CAR T cell therapy in cholangiocarcinoma.
- Location: Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center
- Abstract Number: 1238
- Abstract Title: Histopathologic analysis of mesothelin expression in cholangiocarcinoma supports inclusion in biomarker-targeted clinical trials
- Presenting Author: Adina Vultur, PhD
- Session Title: Exhibits & Poster Viewing
- Session Date and Time: Saturday, Nov. 8, 2025: 12:15 – 1:45 PM, 5:10 – 6:35 PM
- A poster presentation highlighting key considerations for ensuring the timely release of patient materials to support clinical development.
- Location: Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center
- Abstract Number: 591
- Abstract Title: The Need for Speed Without Compromising Quality in Manufacturing Autologous Cell Therapy Products
- Presenting Author: Jacqueline Stief
- Session Title: Exhibits and Poster Viewing
- Session Date: Friday, Nov. 7, 2025: 12:1 5- 1:45 PM, 5:35 – 7 PM
ASH 2025 Annual Meeting
During the ASH annual meeting in the Orange County Convention Center, Orlando, Florida, researchers will present a poster highlighting the potent antitumor activity of SynKIR™-310, a novel CD19-targeted KIR-CAR T cell therapy, in a preclinical mouse model.
- Location: Orange County Convention Center – West Halls B3-B4
- Abstract Number: 4103
- Abstract Title: SynKIR™-310 split-signaling based KIR-CAR T cell therapy achieves faster and deeper anti-B cell tumor efficacy with reduced cytokine levels
- Presenting Author: Megan Blair, PhD
- Session Title: 702. CAR-T Cell Therapies: Basic and Translational: Poster II
- Session Date and Time: Sunday, Dec. 7, 2025: 6:00 PM – 8:00 PM
__
Clinical trials
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma – ClinicalTrials.gov ID NCT05568680
SynKIR-310 for Relapsed/Refractory B-NHL – ClinicalTrials.gov ID NCT06544265
Reference
[1] Incidence of Malignant Mesothelioma. United States Cancer Statistics, CDC, Online. last accessed October 1, 2025.
[2] Health Effects of Asbestos. Agency for Toxic Substances and Disease Registry. CDC. Online. Last accessed on October 1, 2025.
Featured image: ASH 2022 Attendees during General Views at the American Society of Hematology 64th Annual Meeting at the Ernest N. Morial Convention Center. Photo courtesy © 2022 – 2025 ASH/Matt Herp. Used with permission.
DOI
